Leukotriene receptor antagonists do not improve lung function decline in COPD: a meta-analysis

Area of Science:

• Pulmonary Medicine
• Pharmacology

Background:

• Leukotriene receptor antagonists (LTRA) are anti-inflammatory agents with potential therapeutic value in chronic obstructive pulmonary disease (COPD).
• Previous studies on LTRA effects on lung function decline in COPD have yielded inconsistent results.

Purpose of the Study:

• To conduct a meta-analysis evaluating the effects of LTRA on lung function decline in patients with COPD.
• To synthesize evidence from existing cohort and randomized controlled studies.

Main Methods:

• A systematic literature search was performed on PubMed and Embase databases.
• Six studies with a total of 221 COPD patients were included in the meta-analysis.
• Pooled standardized mean difference (SMD) with 95% confidence intervals (CI) was calculated using a random effects model.

Main Results:

• LTRA treatment did not show significant improvements in FEV1 (SMD: 0.28, 95% CI: -0.17 to 0.72), FVC (SMD: 0.54, 95% CI: -0.10 to 1.18), or FEV1/FVC ratio (SMD: 0.18, 95% CI: -0.09 to 0.46).
• Subgroup analysis indicated no benefit from either short-term (<1 year) or long-term (≥1 year) LTRA exposure on lung function decline.
• Statistical significance was not achieved for any of the primary outcomes evaluated.

Conclusions:

• This meta-analysis concludes that neither short-term nor long-term exposure to LTRA improves lung function decline in COPD patients.
• The findings suggest that LTRA may not be an effective treatment for improving lung function in COPD.
• Large-scale randomized controlled trials are urgently needed to definitively establish the role of LTRA in COPD management.